Shionogi/GSK Daily HIV/AIDS Drug Bests Merck’s Twice-Daily In Trials
This article was originally published in PharmAsia News
Executive Summary
Shionogi and GlaxoSmithKline report Phase III trials of their daily HIV/AIDS drug, dolutegravir, performed as well as Merck’s twice-daily Isentress (raltegravir).